FDMT Stock Price
4D Molecular Therapeutics, Inc.
FDMT stock price is $12.25 (+8.89% on the day), giving 4D Molecular Therapeutics, Inc. a market cap of $676.74M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
FDMT Stock Overview
- Price
- $12.25
- Previous close
- $11.25
- Open
- $11.46
- Market cap
- $676.74M
- P/E ratio
- -4.8
- 52-week range
- $6.96 - $16.93
- 1-year price target
- $28.55
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 44
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherland and the United States. The company's lead product candidate, 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with a single, safe, and intravitreal injection; and 4D-710 for the treatment of cystic fibrosis through early-stage studies. It also develops 4D-175 for geographic atrophy in preclinical with open IND; 4D-725 for alpha-1 anti-trypsin deficiency lung disease in preclinical; and 4D-310 for Fabry disease, which is in Phase 1 clinical trials. The company has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; uniQure biopharma B.V; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FDMT | $12.25 | +8.9% | 993.26K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get 4D Molecular Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW